These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 38495490)

  • 1. Advances in Drug Therapy for Metastatic Pancreatic Ductal Adenocarcinoma.
    Gao J; Wang J; Guan C; Shi W; Dong Q; Sheng J; Zou X; Xu Z; Ge Y; Huang Z; Li J; Bao H; Xu Y; Cui Y; Xu X; Zhong X
    J Cancer; 2024; 15(8):2214-2228. PubMed ID: 38495490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Survivors in Metastatic Pancreatic Ductal Adenocarcinoma: A Retrospective and Matched Pair Analysis.
    Rochefort P; Lardy-Cleaud A; Sarabi M; Desseigne F; Cattey-Javouhey A; de la Fouchardière C
    Oncologist; 2019 Dec; 24(12):1543-1548. PubMed ID: 31164454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use and outcomes of chemotherapy for metastatic pancreatic cancer in Australia.
    Body A; Wong R; Shapiro J; Jalali A; McLachlan SA; Ananda S; Lipton L; Cooray P; Gibbs P; Lee B; Lee M
    Intern Med J; 2022 Jan; 52(1):49-56. PubMed ID: 33040452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
    Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
    World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment Patterns in US Patients Receiving First-Line and Second-Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma in the Real World.
    King G; Ittershagen S; He L; Shen Y; Li F; Villacorta R
    Adv Ther; 2022 Dec; 39(12):5433-5452. PubMed ID: 36197644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of patients with advanced pancreatic cancer treated with sequential chemotherapies before the era of modern combination therapy protocols.
    Abendroth A; Noureddine R; Abramczyk M; Paul A; Gerken G; Schmid KW; Markus P; Schumacher B; Wiesweg M; Köhler J; Markus M; Mende B; Dechêne A; Schuler M; Kasper S
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):445-455. PubMed ID: 30430229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review.
    Timmer FEF; Geboers B; Nieuwenhuizen S; Schouten EAC; Dijkstra M; de Vries JJJ; van den Tol MP; Meijerink MR; Scheffer HJ
    Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33807220
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of first-line FOLFIRINOX versus Gemcitabine/Nab-Paclitaxel chemotherapy on survival in advanced pancreatic cancer: Evidence from the prospective international multicentre PURPLE pancreatic cancer registry.
    Santucci J; Tacey M; Thomson B; Michael M; Wong R; Shapiro J; Jennens R; Clarke K; Pattison S; Burge M; Zielinski R; Nikfarjam M; Ananda S; Lipton L; Gibbs P; Lee B
    Eur J Cancer; 2022 Oct; 174():102-112. PubMed ID: 35988408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapy for Metastatic Pancreatic Cancer.
    Ettrich TJ; Seufferlein T
    Curr Treat Options Oncol; 2021 Oct; 22(11):106. PubMed ID: 34665339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
    Huffman BM; Basu Mallick A; Horick NK; Wang-Gillam A; Hosein PJ; Morse MA; Beg MS; Murphy JE; Mavroukakis S; Zaki A; Schlechter BL; Sanoff H; Manz C; Wolpin BM; Arlen P; Lacy J; Cleary JM
    JAMA Netw Open; 2023 Jan; 6(1):e2249720. PubMed ID: 36602796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence.
    Prejac J; Tomek Hamzić D; Librenjak N; Goršić I; Kekez D; Pleština S
    Medicine (Baltimore); 2022 Sep; 101(39):e30566. PubMed ID: 36181099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial.
    Wainberg ZA; Melisi D; Macarulla T; Pazo Cid R; Chandana SR; De La Fouchardière C; Dean A; Kiss I; Lee WJ; Goetze TO; Van Cutsem E; Paulson AS; Bekaii-Saab T; Pant S; Hubner RA; Xiao Z; Chen H; Benzaghou F; O'Reilly EM
    Lancet; 2023 Oct; 402(10409):1272-1281. PubMed ID: 37708904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overall survival of patients with recurrent pancreatic cancer treated with systemic therapy: a retrospective study.
    Gbolahan OB; Tong Y; Sehdev A; O'Neil B; Shahda S
    BMC Cancer; 2019 May; 19(1):468. PubMed ID: 31101022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer.
    Martín AM; Hidalgo M; Alvarez R; Arrazubi V; Martínez-Galán J; Salgado M; Macarulla T; Carrato A
    J Cancer; 2018; 9(11):1978-1988. PubMed ID: 29896283
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group.
    Ettrich TJ; Berger AW; Perkhofer L; Daum S; König A; Dickhut A; Wittel U; Wille K; Geissler M; Algül H; Gallmeier E; Atzpodien J; Kornmann M; Muche R; Prasnikar N; Tannapfel A; Reinacher-Schick A; Uhl W; Seufferlein T
    BMC Cancer; 2018 Dec; 18(1):1298. PubMed ID: 30594153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First- and Second-Line Palliative Systemic Treatment Outcomes in a Real-World Metastatic Pancreatic Cancer Cohort.
    Pijnappel EN; Dijksterhuis WPM; van der Geest LG; de Vos-Geelen J; de Groot JWB; Homs MYV; Creemers GJ; Mohammad NH; Besselink MG; van Laarhoven HWM; Wilmink JW;
    J Natl Compr Canc Netw; 2021 Aug; 20(5):443-450.e3. PubMed ID: 34450595
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.